| Dr Lehien Bui, MD | |
|
501 Bath Rd, 3rd Floor, Bristol, PA 19007-3101 | |
| (215) 785-9799 | |
| (215) 785-9193 |
| Full Name | Dr Lehien Bui |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 501 Bath Rd, Bristol, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134264211 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | MD071810L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lehien Bui, MD 501 Bath Rd, 3rd Floor, Bristol, PA 19007-3101 Ph: (215) 785-9799 | Dr Lehien Bui, MD 501 Bath Rd, 3rd Floor, Bristol, PA 19007-3101 Ph: (215) 785-9799 |
News Archive
The National Science Foundation BIGDATA program awarded $1,200,000 to a research team led by the University of Pittsburgh Swanson School of Engineering to study the big brain data for complex brain disorders and design new algorithms that address computational challenges in multi-site collaborative data mining.
Omeros Corporation today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock to Azimuth Opportunity, Ltd. over a 24-month period. Omeros is not obligated to use the facility and remains free to enter into and consummate other equity, debt and non-dilutive financing transactions. Omeros intends to use the proceeds from future sales of securities under the facility, if any, for general corporate purposes.
Researchers at Oregon State University have discovered a genetic function that helps one of the most important "tumor suppressor" genes to do its job and prevent cancer.
The government's covid-19 travel plan will let new variants into the UK, warn experts in The BMJ today.
The Austrian Breast & Colorectal Cancer Study Group, Alliance Foundation Trials, the Breast International Group, PrECOG, LLC, the German Breast Group, and the NSABP Foundation today announced that the independent Data Monitoring Committee for the global Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study trial determined that the study is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival following a preplanned interim analysis.
› Verified 9 days ago
Dr. Michael Goldstein, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 501 Bath Rd, 3rd Floor, Bristol, PA 19007 Phone: 215-785-9799 Fax: 215-785-9193 | |
Dr. Augusto Adrid, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 501 Bath Rd, 3rd Floor, Bristol, PA 19007 Phone: 215-785-9799 Fax: 215-785-9193 |